Our science and contacts (IIB)
体育直播站the infections and immunity board (iib) supports research into infectious human disease and disorders of the human immune system. this includes and is underpinned by fundamental research into human pathogens, as well as the normal development and functioning of the human immune system, which informs mechanism of disease.
体育直播站the board seeks to support a diverse portfolio of research of relevance to the uk and globally, including in particular (lmics). in addition, the board’s portfolio seeks to address both long-standing questions and support the investigation of emergent higher risk opportunities.
体育直播站the board welcomes submissions on:
- Fundamental discovery research relating to human pathogens, pathogenicity, host pathogen responses and immune system development, function and disorders. Including use of in silico systems, relevant animal models and experimental studies in humans.
- Population-level research, using epidemiological, genetic and ‘omic approaches, and computational modelling, to elucidate disease risks, aetiologies and progression, and to understand the evolution of pathogen populations.
- Research to inform novel strategies for preventing and controlling infectious and immune disease, including vector control, predictive modelling and early development research to inform future intervention strategies.
For applications addressing LMIC priority diseases, please refer to the Official Development Assistance/research principles section of our International and global health: Remit and science we support体育直播站 page.
For applications for fellowships please refer to our Fellowships page. For studies undertaking the development, validation or evaluation of new products/interventions please see our Translational research and Global health funding partnerships pages.
please, note that all applications for funding for new or existing population cohort studies are required to submit an outline for assessment by the cohort strategic review group (). applications for funding for clinical (i.e. patient-specific or disease-focused) cohorts need not follow this process).
the board has identified key challenges that can only be met with a more integrated approach across our portfolio. these form current board opportunity areas, which will be used by iib to prioritise investments during funding discussions, together with the three cross-board opportunities. we encourage researchers to submit applications that focus on:
- Antimicrobial Resistance
体育直播站antimicrobial resistance (amr) is an important global health challenge and a priority for the mrc. while discovery research to better understand pathogen virulence and identify targets for new prevention strategies, diagnostics and therapies is well represented in our portfolio, there is a risk that these discoveries are not taken forward to deliver impact to patients. to address this issue, iib will prioritise interdisciplinary approaches developing new interventions to contain, control and mitigate amr in bacteria, fungi, parasites and viruses.
- Data integration and systems approaches – from data to insight
novel insights can be gleaned through appropriate linkage of data across different dimensions (‘omic, single-cell, cell populations, organ systems, individuals, populations, countries, etc.). this requires engagement with bioinformaticians and statisticians during the conceptualisation phase, to formulate compelling research questions and to develop integrative approaches with the potential for significant insight. these insights can be built upon using a systems approach of iterative cycles of modelling and experimentation.
体育直播站the board expects to retain its opportunities for at least three years, although they will be assessed each year and individually may be refreshed in line with developments. applicants are expected to justify how their proposed research addresses an opportunity.
- Global health and research underpinning epidemic preparedness
the board seeks to:
- Maintain the momentum generated through the GCRF Infections Foundation Awards, the Zika Rapid Response Initiative and our support for Networks in vector borne disease and vaccines R&D, through follow-on submissions made from projects and networks supported by these initiatives.
- Enhance research underpinning epidemic preparedness, such as, but not limited to, relevant research into internationally recognised priority pathogens, for example, those on the WHO R&D Blueprint and UK Vaccine Network lists and non-seasonal influenza.
- Immunity and infection through the life course
- To further develop the Board’s portfolio of studies on how immune status and infection can contribute to disease and to link with the interests of sister Boards (c.f. mental health and neurodegeneration, NMHB; asthma, PSMB; cancer, MCMB), submissions examining the driving causative linkages between immune status/infection and disease.
体育直播站in addition to the board opportunities, iib will prioritise for consideration submissions that meet the criteria of mrc-wide opportunities, which apply to all boards. these are:
- New Investigator Research Grants - supporting researchers towards becoming independent investigators.
- Experimental medicine - understanding disease mechanisms and therapeutic targets using human participants.
- Advanced therapeutics - including cell/gene therapy, regenerative medicine, innovative medicines.
iib also supports research areas identified by the mrc as a high priority:
Details on how applications that fall into the scope of the Board or cross-Board opportunity areas are assessed during the review process, is explained in the Ranking section of our Funding meetings page.
if you have a query about scientific aspects of your research proposal, or a remit question regarding which board or scheme your proposal should be assessed by, please contact the programme manager shown below against your scientific area:
Programme Manager for immunology
Vacant – IIB@wnjrkh.icu
- Normal immunology: including cellular and molecular immunology & inflammation – basic mechanisms, cellular and molecular inflammation
- UK and global health research in:
- Immune disease: including allergy (except asthma, IBD/Crohn’s disease, and other organ-specific disorders), transplantation immunology, systemic immune disorders & auto-immune disease
- Host response to pathogens
Programme Manager for vaccines, neglected tropical diseases and vector-borne diseases
- Dr Martin Broadstock – email@example.comBasic, applied and translational research into parasitology that informs the diagnosis, treatment, prevention and mechanism of human disease.
- UK and global health research in:
- Vaccine research
- Parasites, e.g. Malaria, neglected tropical diseases (NTDs) such as leishmaniasis, trypanosomiasis
- Arboviruses, e.g. Zika, yellow fever
- Transmission and control of infectious agents including research into vector control of human infections.
Programme Manager for fungal and viral infections
Dr Anna Kinsey – Anna.Kinsey@wnjrkh.icu
- Basic, applied and translational research into medical mycology and virology that informs the diagnosis, treatment, prevention and mechanism of human disease.
- UK and global health research in:
- Viral infections (not arboviruses), e.g. Influenza, Hepatitis viruses, HIV, Haemorrhagic fever viruses, Coronaviruses and Henipaviruses
- Fungal infections, e.g. Aspergillus, Candida
- Transmission and control of viral and fungal infectious agents.
- Pandemic preparedness.
Head of Programme – Antimicrobial Resistance
Dr Jessica Boname – Jessica.Boname@wnjrkh.icu
- Basic, applied and translational bacteriology that informs the diagnosis, treatment, prevention and mechanism of human disease.
- UK and global health research in bacterial infections, with particular emphasis on bacteria on the list.
- Antimicrobial resistance – research to protect us from infection and disease, prevent the development of further resistance in the antibiotics we currently have and promote the development of new therapies.
- Transmission and control of bacteria including zoonoses.
- Tackling Antimicrobial Resistance – UKRI Cross Council Initiative
- Joint Programming Initiative on AMR (JPIAMR)
Head of Infections and Immunity
Dr Joanna Jenkinson – Joanna.Jenkinson@wnjrkh.icu
Programme Manager for methodology and clinical research
General policy and eligibility enquiries
For specific IIB enquiries please contact: IIB@wnjrkh.icu
For general queries about MRC policy and eligibility please contact Research Funding Policy and Delivery team: RFPD@wnjrkh.icu
For queries about submitting your application using the online, electronic submissions system, Je-S, please contact the Je-S Helpdesk, JeSHelp@je-s.wnjrkh.icu or 01793 444164
If you have a query about the peer review of a research proposal, either as an applicant, reviewer or Board/Panel member, please contact PeerReview@wnjrkh.icu